| Logo | Name | Σ | Employees |
|---|---|---|---|
 |  Orio Therapeutics At Orio Therapeutics, our mission is to save lives by making the regenerative medicine dream accessible and a wide-spread reality. We are dedicated to developing novel regenerative drugs with increased efficacy and reduced side-effects, using cutting-edge targeted drug-delivery technologies to create novel therapeutic proteins. Notably, we strive to demonstrate that efficient drug delivery technologies are not confined to the development of complex devices and drug carriers but can be achieved based on clever molecular designs. We aim to initially validate our program pipeline through the development of a therapeutic molecule for myocardial infarction that has the potential to change the … 54 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 3 |
 |  Regulaxis SAS Regenerative Medicine - Growth Disregulation - Oncology REGULAXIS is a French innovative biotechnology company based at BIOCITECH the technology park of life science of Paris North area. The company is engaged in the research, development and licensing of innovative synthetic molecules for use in human therapies. Its mission is to grant licenses of innovative molecules in a pharmaceutical company after the establishment of a phase II clinical record. REGULAXIS leads its R&D on its own premises, particularly in regard to biochemical and biological experiments, and keeps the mastery of the chemical synthesis of its therapeutic molecules. The company develops its … 253 similar entities Type: Startup Activities: biotech healthtech Technologies: Synthetic Biology | 0 | 2 |
 | Astraveus We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. biotech, medtech, cell therapy, gene therapy, CAR-T, MSC, iPS, ATMP, Tissue Engineering, cell based therapies, biotherapies, RMAT, and Manufacturing 453 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 18 | 69 |
 | NanoMedSyn NanoMedSyn develops a new delivery platform to create first-in-class drugs by the engineering with patented AMFA vectors NanoMedSyn was born from the fundamental research of its biologist and chemist founders who discovered a breakthrough technology for drug delivery to the lysosomal cell compartment leading to potentiation of therapeutics. This technology, validated at the preclinical level, has a wide range of applications in the fields of oncology, immunity, inflammation or metabolism. NanoMedSyn’s development plan is based on a strong intellectual property of patented synthetic derivatives called AMFA. The main application is the engineering of recombinant proteins like antibodies or enzymes for … 157 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 5 |
 |  Pharvaris Pioneering science for patient choice Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically … 66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 133 |
 | Harness Therapeutics Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases neurodegeneration, RNA therapeutics, physiological upregulation, post-transcriptional upregulation, mRNA, ASO, and SINEUP 305 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 2 | 33 |
 | VeonGen Therapeutics GmbH Dedicated to develop the medicines of the future VeonGen Therapeutics (formerly known as ViGeneron) was founded in 2017 as a spin-off of the Ludwig-Maximilians-University (LMU) Munich. At VeonGen Therapeutics we are dedicated to develop innovative gene therapies based on our two unique and proprietary technology platforms. VeonGen Therapeutics will leverage its two technology platforms to address unmet medical needs with in-house gene therapy programs for selected retinal disorders. Together with partners we will exploit our VeonGen Therapeutics technologies for additional indications. Gene Therapy, Inherited Retinal Disorders, and AAV vector 57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 9 |
 | Concinnity Genetics Improving the safety and efficacy of gene therapies using AI Concinnity is developing an AI-driven RNA design platform to build gene control systems for gene and cell therapies. Our RNA-based control systems will form part of the gene therapy cassette and enable precise control of therapeutic activity. Such control systems have huge potential to enhance both patient safety and therapeutic efficacy, for example by allowing a gene therapy to dynamically adjust its activity in response to patient disease state, recognise tissue type, or by allowing clinical control of the therapy after administration. Gene Control, RNA, Artificial Intelligence, Synthetic Biology, and … 42 similar entities Type: Startup Activities: deeptech Technologies: A.I. Synthetic Biology | 0 | 10 |
 | AbLeads AbLeads is a young biotech startup developing innovative solutions in Oncology, through the generation of novel, personalized therapeutic antibodies. Learn More on https://ableads.fr Biotechnology, Oncology, Immunotherapy, Therapeutic Antibodies, and Personalized Medicine 609 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 1 |
 | Immitra Bio GmbH A scalable in-vivo genetic medicine platform At Immitra Bio, we are pioneering a novel genetic medicine platform. Our innovative approach enables precise, durable, and safe gene modifications within blood stem cells, laying the foundation for scalable, curative in-vivo therapies. 78 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 2 |
 | Tribune Therapeutics Targeting CCN signaling to treat fibrosis Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. 177 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 15 |
 | Wave Life Sciences Unlocking the broad potential of RNA medicines to transform human health We are a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Our RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Our diversified pipeline includes clinical programs in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, … 59 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology | 7 | 368 |
 | aptaTargets Pioneering therapies based on aptamer technology aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept. Biopharmaceutical, Biotechnology, Aptamers, Immunology, Stroke, and Inflammatory diseases 134 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 12 |
 | Aurion Biotech We're on a mission to cure blindness with our transformational platform of advanced therapies. Aurion Biotech is a clinical stage biotech company, developing a transformational platform of advanced therapies to cure blindness. Our first candidate is for the treatment of corneal endothelial disease, and one of the first clinically validated cell therapies for corneal care. CAUTION: New Drug—Limited by Federal (or United States) law to investigational use. 64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 97 |
 | SynaptixBio Ltd. Developing therapies for severe leukodystrophies Overview SynaptixBio is a rare disease biotech company that is pioneering ground-breaking treatments for severe leukodystrophies and other childhood neurodegenerative diseases. SynaptixBio’s mission is to deliver gene therapies for fatal leukodystrophies in children caused by loss of function or mutation in a single gene. Using a breadth of platforms including antisense oligonucleotide (ASO)-based technology, we can silence the expression of the toxic gene to reverse disease progression. This approach will create life saving treatments for severe genetic diseases that affect the central nervous system. Pharmaceutical, Biotech, Leukodystrophy, Rare Disease, H-ABC, Hypomyelination, Basal Ganglia, Cerebrllum, Neurology, … 58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 5 |
 | Alia Therapeutics On-target gene therapies Alia Therapeutics is a pioneering gene editing company with a vision to revolutionize medicine by curing genetic diseases at their roots. Alia’s versatile portfolio of novel CRISPR systems expands the range of targetable genomic sites and increases the precision of genetic modifications, bringing gene editing to the next level of specificity and safety, which are required for therapeutic applications. 60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 14 |
 | Kano Therapeutics Complete genes for complete cures Kano Therapeutics is a biotech startup enabling safe, effective, and flexible correction of gene-length stretches of DNA through a new class of biomaterials: circular single-stranded DNA. By building a “one stop shop” product development platform for single-stranded DNA templates that combines manufacturing, application, and computational tools we bridge the gap between editing genes and totally replacing them. Biotechnology, DNA therapeutics, Gene therapy, CRISPR, and Biological engineering 108 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 15 |
 | Abtech Therapeutics Expertise in protein engineering | in silico & in vitro antibody discovery platform We work in partnership with technology platforms, pharmaceutical companies, and academic research groups to create next generation cell and molecular therapies. We integrate novel technologies into a synthetic antibody platform to provide the most advanced discovery engine possible. 290 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 2 |
 | HHC medical Revolutionizing drug delivery HHC medical is a health tech startup developing a platform technology for targeted and non-invasive drug delivery via wireless electroporation. Drug Delivery, Genetic therapies, and Enabling life-altering therapies 439 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology | 2 | 46 |
 | AlveoGene Transforming Rare Respiratory Disease Outcomes Using Inhaled Genes Therapy AlveoGene is an innovative company focused on transforming rare respiratory disease outcomes using inhaled gene therapy. AlveoGene has been created by OSE, Harrington and OCC in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC). The GTC was founded in 2001 to catalyse the application of pioneering research to gene therapy development and manufacturing related to cystic fibrosis and other respiratory diseases, and originated at Imperial College London and the Universities of Oxford and Edinburgh. AlveoGene has secured an exclusive licence to a proprietary and validated … Type: Startup Activities: manufacturing deeptech biotech Technologies: Synthetic Biology | 1 | 4 |
 | Op2Lysis A New Hope for Hemorrhagic Stroke Op2Lysis develops new treatments for patients suffering from thrombosis at the cerebrovascular level, with an initial focus on the hemorrhagic form of stroke. Indeed, there is no currently approved and available therapeutic solution for these patients. The company develops its game-changing NANOp2Lysis platform, associating a breakthrough vectorisation technology, industrial know-how enabling clinical quality production, and preclinical expertise to propose predictive and translational models, a first in this field. O2L-001, the first product resulting from this technology, will soon enter regulatory toxicology with the aim of applying for clinical trial authorisation in patients in North … 26 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 6 | 4 |
 | Advesya Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune 424 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 11 | 4 |
 | Genvade Therapeutics Dedicated to developing treatments for rare diseases originated from nonsense mutations Genvade aims to harness the power of nonsense mutation readthrough molecules to develop treatments for some of the most burdensome rare diseases. Our lead compound targets indications include cystic fibrosis, Duchenne muscular dystrophy and other genetic diseases. small molecules, drug discovery and development, rare diseases, nonsense mutation corrector, cystic fibrosis, genetic diseases, oncology, readthrough, and Duchenne 97 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | N/A |
 | ResoTher Pharma Building on innovative science to create treatments for patients in need ResoTher Pharma ApS is a biotechnology company focused on developing novel and effective peptide therapeutics for cardiovascular disease by targeting inflammation. Biotechnology, Drug Development, and Pharmaceutical Industry 715 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 20 |
 | PepGen Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics 483 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 63 |
 | Neocor Therapeutics Neocor is dedicated to pioneering transformative therapies in cardiac care We are currently developing a novel gene therapy approach targeting ischemic and rare genetic cardiac diseases, and moving from lab preclinical trials to regulatory trials. The Company was founded in October and has received strong traction since inception. We will be looking to strengthen our human and financial ressources in the coming month in order to start the regulatory pre clinical trials. gene therapy, biotechnology, rare disease, and cardiology 124 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 6 | 5 |
 | Fuse Vectors Catalyzing Gene Therapy | Revolutionary Technology for Revolutionary Therapies At Fuse Vectors, our mission is to revolutionize AAV gene therapy development. Traditional cell-based technologies have hindered progress, posing challenges in safety, efficacy, development time, and cost. Our Cell-Free AAV technology surpasses these methods, producing safer, more effective, and cost-efficient AAV viral vectors in a fraction of the time. 28 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology | 3 | 11 |
 | Kezar Life Sciences Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be … 168 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 43 |
 | PulseSight Therapeutics PulseSight is an ophthalmology drug development company developing disruptive non-viral gene therapies with minimally-invasive delivery technology to treat major eye diseases. Our mission is to develop life-changing solutions for patients with diseases leading to sight loss. 78 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 12 | 10 |
 | Vivet Therapeutics Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through collaborating with the Fundacion para la Investigacion Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression. Gene Therapy 86 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 4 | 17 |
 | ILC Therapeutics ILC Therapeutics is a specialist UK-based developer of hybrid interferons, a new engineered drug class with improved therapeutic profiles, enabling broad applications across multiple indications. Hybrid interferons combine favourable attributes of specific natural interferon sub-types to produce novel drug candidates designed to deliver reduced toxicity and improved efficacy. ILC Therapeutic’s platform approach has produced two first-in-class lead candidates, AlfacyteTM and DermacyteTM focused on antiviral and dermatological indications respectively, which are progressing towards the clinic. Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 5 |
 | CRISPR Therapeutics Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients … 52 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 12 | 370 |
 | Axovia Therapeutics Driving gene therapy breakthroughs to develop transformative AAV treatments for patients with ciliopathies like BBS Axovia Therapeutics is dedicated to the research and development of novel AAV gene therapies that target key aspects of ciliopathies, addressing the devastating impact of the disease head-on for patients, their families and caregivers. Axovia is currently developing therapies for patients with mutations in the BBS1 gene which manifests as Bardet Biedl Syndrome. Our initial goal is to halt the progression of BBS by targeting the most debilitating aspects of the neurological, metabolic and retinal dysfunctions. Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 8 |
 | AviadoBio A revolution in gene therapy for neurodegenerative disorders. At AviadoBio, we are relentlessly chasing cures by translating groundbreaking science and precision delivery into life-changing medicines for people living with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). With our deep understanding of the brain and our suite of proprietary gene therapy platforms and delivery technologies, we are working relentlessly to overcome the challenges of delivering the right drug to the right place. Our innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to halt or potentially reverse neurodegenerative diseases. The Company’s technology is based on pioneering … 51 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 71 |
 | Spur Therapeutics Toward the next generation of gene therapy. Spur Therapeutics (formerly Freeline Therapeutics) is a clinical-stage biotechnology company focused on developing life-changing therapies for debilitating chronic conditions. By optimizing every component of our product candidates, we are improving genetic expression and targeted delivery to realize outsized clinical results. Building on the successes of our two potential first-in-class therapies for Gaucher disease and adrenomyeloneuropathy (AMN), we’re moving from rare diseases toward more widespread conditions, including forms of Parkinson’s and dementia, and even certain cardiovascular diseases. Expanding our impact, and pushing forward to new frontiers of genetic medicine. Toward life-changing therapies, and brighter … 96 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 329 |
 | Integra Therapeutics Integra Therapeutics is a biotech company engineering the next generation of gene writing tools to cure genetic diseases At Integra Therapeutics we have combined the precision of CRISPR systems with the gene transfer efficiency of viral integrases and transposases. Harnessing what nature has evolved to introduce large pieces of DNA into the genome, together with the precision of sequence specific DNA binding proteins, has allowed for unprecedented efficiency in programmable gene delivery. 111 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 8 | 24 |
 | Ethris Clinical stage biotech company focused on development of disruptive mRNA therapeutics for severe respiratory diseases Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients’ cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners. Biotechnology, mRNA, LNPs, Vaccines, Therapeutics, Formulation, and Manufacturing 127 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 40 |
 | Genewity B.V. Genewity is a biotech company developing autologous cell and gene therapies. 302 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 14 |
 | Infinitopes Preventing deaths from cancer metastases Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, we are empowering the immune system to fight cancer metastases with unique, de novo antigen discovery technologies, innovative high efficiency vectors and intelligent clinical trial design. Our mission is to significantly enhance patient survival. 306 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 10 | 27 |
 | THERAVECTYS Based in Paris and in the USA, TheraVectys is an immunotherapy company spun off from the Institut Pasteur created in 2005 by Dr. Pierre Charneau. TheraVectys is pioneering the application of novel lentiviral vector technology to address most of unmet and critical medical needs. By creating the only Joint-Laboratory between a private company and the Institut Pasteur in Paris, TheraVectys develops an extensive pipeline of vaccine candidates to drive the widespread treatment and prevention of cancer and infectious diseases. Leveraging our proprietary technology platform, and the extensive virology expertise of the Institut Pasteur, TheraVectys provides a robust and highly effective … Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology | 2 | 18 |
 | Astellas Gene Therapies Follow Astellas Pharma for updates on our pipeline of genetic medicines for patients with rare diseases. The Astellas Gene Therapies page is no longer active or monitored. gene therapy and biotechnology 51 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 3 | 406 |
 | GenEdit Delivering the potential of genetic medicines GenEdit is focused on overcoming the major challenge to genetic medicines: Delivery. We aim to overcome this limitation and enable treatment of a broad range of diseases, having a positive impact on the lives of as many people as possible. The foundation of our company is our NanoGalaxy platform. NanoGalaxy contains a library spanning thousands of unique non-viral, non-lipid, polymer nanoparticles. Using our iterative screening process, we are able to identify polymer nanoparticles that can deliver the needed genetic medicine payload to the needed tissue to treat disease. We are focusing our research on … 36 similar entities Type: Startup Activities: biotech deeptech nanotech Technologies: Synthetic Biology | 0 | 61 |
 | Ksilink Patient-based drug discovery We design and apply unique patient-based cellular assays for large-scale phenotypic screening, leaning on the power of AI-driven image analysis. Integrated from bed to bench and back to bed, we aim to generate most efficient first-in-class therapeutic molecules for next generation medicine. AI image and data analysis, biology, high content screening, high throughput screening, deep learning, assay development, patient stratification, pyschiatric disorders, and cardiac muscle 256 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: A.I. Synthetic Biology | 4 | 14 |
 | MiNA Therapeutics Activating RNA, mastering disease Harnessing an innate mechanism of gene activation, MiNA Therapeutics' platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases. Gene activation, RNA therapeutics, Liver disease, and Drug discovery 221 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 4 | 26 |
 |  Corlieve Therapeutics At Corlieve, we are focused on bringing novel therapeutic options to patients with severe neurological disorders. Corlieve Therapeutics, a fully owned subsidiary of UniQure, is a biotechnology company focused on bringing novel therapeutic options to patients with severe neurological disorders. 49 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 2 | 1 |
 | NERVOSAVE THERAPEUTICS Innovative therapies for peripheral nerve diseases Nervosave Therapeutics discovers and develops therapies that slow, stop and reverse a broad range of demyelinating peripheral nerve diseases. Our first aim is to develop best in class Gene Therapy for CMT1A patients and beyond for all demyelinating CMT diseases. We develop robust discovery programs targeting both CMT diseases and acquired demyelinating peripheral neuropathies such as diabetic peripheral neuropathy and Guillain-Barré syndrome. 8 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 11 | 2 |
 | Harmonix Innovative platform to transport and deliver viral and non-viral gene therapies to the central nervous system Harmonix, a breakthrough technology to deliver molecules, including viral and non-viral gene therapy, in a targeted and non-invasive manner, in the central nervous system. We develop innovative microbubbles who are able to encapsulate molecules and deliver them in a non invasive way in the brain. Biotech, Central Nervous System, Gene delivery, Non-viral and viral gene delivery, Research, and Glioblastoma 66 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 34 | 4 |
 | AVROBIO Clinical-stage lentiviral gene therapy company, powered by plato®. Our vision: bring personalized gene therapy worldwide Our vision is to bring personalized gene therapy to the world. We target the root cause of genetic disease by introducing a functional copy of the affected gene into patients’ own hematopoietic stem cells (HSCs), with the goal of durably expressing the therapeutic protein throughout the body, including the central nervous system. Our first-in-class pipeline includes clinical programs for Gaucher disease and Hunter syndrome, as well as a preclinical program for Pompe disease. Our proprietary plato® gene therapy platform is scalable for planned global commercialization. … 38 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 4 | 16 |
 | Voyager Therapeutics, Inc. Leveraging genetics to treat neurological diseases Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACERTM AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs … 58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 175 |
 | ReCode Therapeutics Powering the next wave of genetic medicines through superior delivery ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. RNA Therapies, Genetic Medicines, Non-Viral Lipid Nanoparticles, Genetic Respiratory Disease, Cystic Fibrosis, Primary Ciliary Dyskinesia, and Biotechnology 81 similar entities Type: Startup Activities: deeptech biotech nanotech Technologies: Synthetic Biology | 6 | 75 |
 | Circio Holding ASA Developing novel circular RNA and immunotherapy medicines. Circio Holding ASA is a clinical stage company developing immune activators to target difficult-to-treat diseases. The company’s mission is to deploy vector-based technology to create a novel class of targeted, multi-functional circRNA medicines. It has established a cutting-edge circular RNA (circRNA) program and is collaborating with Prof Michael Uhlin and a team at the Karolinska Institutet in Stockholm with the intent to develop next generation RNA therapeutics for various applications. The company also has a mutant RAS cancer vaccine program, with two collaborative clinical trials underway in the USA and Norway. It is … 31 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 18 |
 | MEDSENIC New therapeutic targets based on arsenic trioxide (As2O3) Founded in 2010, MEDSENIC is a biopharmaceutical start-up that aims to exploit the new possibilities offered by the therapeutic use of arsenic trioxide (As2O3) and thereby provide a treatment for patients with autoimmune diseases. santé, biotechnologies, bioparma, biopharmaceutical, biotech, health, biotechnology, autoimmune diseases, and maladies auto-immunes 361 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 1 |
 | Pencil Biosciences Limited Developing the Next Generation Gene Editing Technology Pencil Biosciences is developing a truly innovative gene modulation technology that can have an impact across a range of applications, including new therapeutic options for patients with rare diseases. Genome Engineering, Research and Development, and Gene Editing 328 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 17 |
 | Casebia Therapeutics An innovative gene editing company discovering and developing curative treatments for genetic diseases Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing … 82 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology | 0 | 1 |
 | RNatives Developing precision RNA-based gene regulating therapies RNatives is a biotechnology company developing precision RNA-based gene regulating therapies by leveraging its RNAIntel platform which identifies small non-coding RNAs that bind directly to gene promoters to regulate gene expression. The Company is developing novel RNA-based therapies to treat ocular, CNS, and metabolic diseases, as well as cancer. The Company's technology is based on years of academic research published by Turunen et al. | 0 | 10 |
 | UNITY Biotechnology UNITY is harnessing pathways of aging biology to develop new medicines, with a focus on retinal diseases. As pioneers in cellular senescence, UNITY is advancing the first senolytic therapeutic candidate for retinal diseases that aims to restore diseased tissue to a healthier state, a potentially paradigm shifting treatment in ophthalmology. 50 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 2 | 20 |
 | Sio Gene Therapies Pushing the boundaries of gene therapy to develop treatments for debilitating neurodegenerative diseases. Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Our current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies. We are also expanding the reach of gene therapy to highly prevalent conditions such as Parkinson’s disease, which affects millions of patients globally. Led by an experienced team of gene therapy development … 33 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 29 |
 | REGENXBIO Seeking to improve lives through the curative potential of gene therapy. REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with … 12 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology SaaS | 2 | 392 |
 | Caribou Biosciences Clinical-stage biopharmaceutical company developing transformative therapies to treat devastating human diseases Caribou Biosciences is a leading clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Our next-generation genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. We believe the future of cell therapy is off-the-shelf, and we are advancing our pipeline of off-the-shelf, or allogeneic, cell therapies from our CAR-T cell therapy platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Next-generation CRISPR genome editing, allogeneic CAR-T cell therapies, oncology, and … 81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 11 | 134 |
 | Ligandal Ligandal is developing precision molecular therapeutics and targeted delivery technologies. Ligandal is a genetic medicine company that uses nanotechnology to develop targeted and personalised therapies. As a regenerative medicine biotechnology company, Ligandal develops ultra-rapid therapeutics and vaccines for outbreaks and pandemics, in addition to its work in immuno-oncology and rare genetic diseases. Our current focus is on delivering a peptide-based cure to the COVID-19 pandemic (SARS-CoV-2 coronavirus), as part of a broader mission of enabling personalized medicine on a global scale through the power of nanomedicine and gene therapies. Given that increasingly complex disease states require precise and custom-tailored medicine, … 22 similar entities Type: Startup Activities: biotech deeptech healthtech nanotech Technologies: Synthetic Biology | 2 | 12 |
 | SYLENTIS Sylentis is an European biotechnological company founded in 2006. Sylentis focuses on researching new therapeutic approaches based on gene silencing. Our company is specialised in developing ophtalmologic therapies via interference RNA, a powerful tool for rational drug design. Most advanced product of the company are treatments for glaucoma and dry eye syndrome. Sylentis is a wholly owned member of PharmaMar (www.pharmamar.com) Gene Sinlencing, siRNA RNAi Drugs, Ophtalmology, Biotechnology, RNAi, R&D, Pharmaceuticals, Bioinformatics, Biotecología, Biotech, Experimental drugs, Glaucoma, Dry eye syndrome, Target Therapies, Production, eyes diseases, RNAi Clinical Trials, Ophthalmology, Licensing, Research, Drug Discovey, and Rational Design Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 54 |
 | AATec Medical Unlocking the therapeutic potential of AAT AATec Medical GmbH is a biotech company developing a product platform based on recombinant alpha-1 antitrypsin (AAT) for the treatment of inflammatory diseases, virus infections and rare diseases. The first product candidate is a novel AAT formulation for inhalation to treat emerging inflammatory diseases of the lung and respiratory virus infections. 50 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology | 0 | 8 |
 | Acceleron Pharma Accelerating drug discovery to transform patients' lives Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com Biopharmaceuticals, Orphan Disease Therapeutics, Rare Diseases, and Serious Diseases 658 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology | 6 | 67 |
 | Somagenetix Cure with genes Healthy cells for healthy people Somagenetix is a new company that aims at becoming a leading gene therapy company with first-in-class treatment for phagocyte-related disorders. We are spin-off from the University of Zurich and we are leveraging world-class scientific and clinical expertise to solve unmet medical needs through gene therapy. Carried by a highly experienced scientific team with over 17 years experience in gene therapy research, clinical development and applications, our mission is to cure all patients with Phagocyte Disorders. A cutting-edge technology with a complete & unique platform solving all challenges of ex-vivo gene therapies: specificity, … 44 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 10 |
 | Immunocore Science to Transform Lives Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. See our community guidelines: http://bit.ly/2kFA8hr Biotechnology, Cancer, Oncology, Infectious Diseases, Autoimmune Diseases, T Cell Receptor, Immunotherapy, ImmTAX, ImmTAC, ImmTAV, and ImmTAAI 280 similar entities Type: Startup Activities: deeptech hrtech biotech Technologies: Synthetic Biology | 10 | 591 |
 | ONA Therapeutics First-in-class ADCs tailor designed to attack advanced cancer Ona Therapeutics is pioneering the development of first-in-class antibody drug conjugates (ADCs) that exploit the molecular underpinnings of advanced cancer. We partner with renowned academics and clinicians to discover novel therapeutic targets from the unique biology of treatment refractory advanced cancer patients. Our approach combines privileged biology with Ona’s expertise in biologics. Together, we craft ADCs and antibody therapies, aiming to provide effective new treatments for patients with no remaining alternatives. 75 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 35 |
 | LabGenius Therapeutics Combining human and machine intelligence to discover the next generation of therapeutic antibodies. LabGenius Therapeutics ("LabGenius") is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company’s discovery platform, EVATM, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. While EVATM is both modality and format-agnostic, LabGenius' internal pipeline is focussed on the development of selectivity-enhanced antibodies for the treatment of solid tumours. The company's novel approach is delivering a pipeline of antibody therapeutics with best-in-class killing profiles. Medical, Health, and DNA Libraries 57 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: A.I. Robotics Synthetic Biology A.I. - Machine Learning | 19 | 66 |
 | Antion Biosciences SA Engineering smarter gene modulation for breakthrough cell and gene therapies Antion Biosciences is a Swiss biopharmaceutical company developing novel gene and gene-modified cell therapies tools. Antion has developed a proprietary gene engineering technology with unmatched versatility to overcome key challenges facing cell and gene therapy. Our patent-protected technologies are versatile, highly effective and broadly applicable to various therapeutic areas. We actively explore collaborations and partnering opportunities to out-license our proprietary technologies. Gene and Cell therapies and Genetic engineering 60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 11 |
 | AAVantgarde Pioneering treatments for Stargardt disease and Usher 1B, addressing the root cause of the disease AAVantgarde is a clinical stage, biotechnology company advancing best-in-class therapies for patients with inherited retinal diseases (IRDs). With a strong foundation in translational science and a commitment to clinical excellence, AAVantgarde is working to bring transformative therapies to patients. Gene Therapy, Ophthalmology, and Rare diseases 63 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology | 1 | 62 |
 | Seamless Therapeutics Seamless Therapeutics is overcoming the boundaries of gene editing by unlocking the full potential of recombinases. Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. Our technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes. We are applying our proprietary know-how to develop a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing. 40 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology | 1 | 37 |
 | AveXis, Inc. AveXis is now Novartis Gene Therapies Novartis Gene Therapies (formerly AveXis) is reimagining medicine to transform the lives of people living with rare genetic diseases. Utilizing cutting-edge technology, we are working to turn promising gene therapies into proven treatments, beginning with our transformative gene therapy for spinal muscular atrophy (SMA). Follow us on LinkedIn: https://www.linkedin.com/company/novartis-gene-therapies/ How to reach us: Novartis Gene Therapies 2275 Half Day Road, Suite 200 Bannockburn, IL 60015 Email: gtx.communications@novartis.com Office Phone: 847.572.8280 Toll-free Phone: 844.428.3947 Gene Therapy, Synthetic Biology, and Spinal Muscular Atrophy 58 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 107 |
 | Enhanced Genomics Transforming therapeutic development through functional genomics Enhanced Genomics is a pioneering functional genomics company harnessing its proprietary 3D genomics technology to transform drug target discovery. By integrating 3D genomics with multi-omics approaches, Enhanced leverages 3D Multi-omics to deliver unparalleled insights into gene regulation and disease mechanisms. This innovative approach accelerates the development of novel therapeutics across a wide range of disease areas. 60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 23 |
 | NewBiologix Developing technologies for the biopharma industry to allow them to treat the root causes of diseases and disorders. Based in Lausanne, Switzerland, NewBiologix SA is a technology innovation company developing a proprietary and breakthrough DNA integration platform for the advanced engineering of human and mammalian cell lines for the improved production of viral vectors used in gene therapies. gene therapy, cell therapy, next-generation sequencing, NGS, rAAV, viral vectors, biologics, stable cell lines, Genomic Integration, stem cell, bioinformatics, capsid optimization, HEK293, gene expression, ATMPs, genomic, epigenetic, transcriptomic, mammalian cell lines, and human cell lines 295 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology | 2 | 25 |
 | Closed Adverum Biotechnologies We are on a global mission to establish gene therapy as a new standard of care for the leading causes of vision loss. Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its … 10 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology | 0 | 192 |
 | Pacira Germany High-Capacity Gene Therapy Vector Platform to Address Prevalent Diseases Now part of Pacira Biosciences. GQ Bio is pioneering a high-capacity gene therapy vector platform (HCAd) that addresses some of the big challenges in the gene therapy field: Transfer of large and multiple genes with a single vector, highly efficient gene delivery (high transduction efficiency), and large-scale manufacturability. Based on its HCAd vector platform, GQ Bio develops transformative treatments for chronic, prevalent conditions such as osteoarthritis and intervertebral disc degeneration. GQ Bio is headquartered in Hamburg, Germany and has sites at Luckenwalde (greater Berlin area), Germany and Liège, Belgium. biotechnology, gene … 51 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 21 |
 | Accure Therapeutics R&D pharma dedicated to developing innovative medicines to treat patients suffering from Central nervous system diseases A new medicine R&D engine (R&D pharma company) operated by an experienced team dedicated to the discovery and development of new medicines to treat patient suffering from severe diseases of the central nervous system. Accure Therapeutics focuses on neurons that suffer a dysfunction, and on the glial environment that supports them, in an attempt to impede their degeneration and death. We work to find new medicines that correct the pathological changes that are responsible for the disease, and that produce beneficial outcomes (i.e. Disease … 56 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 12 |
 | uniQure Transforming the lives of patients through gene therapy uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases. aav, Huntington's disease, gene therapy, ALS, epilepsy, and Fabry disease 172 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 2 | 319 |
 | AC Immune Shifting the treatment paradigm for neurodegenerative disease towards precision medicine and disease prevention. AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, including five in Phase 2 development and one in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting … 23 similar entities Type: SMB Activities: healthtech biotech deeptech Technologies: Synthetic Biology | 9 | 165 |
 | MedXCell SA The Cell Therapy Venture Builder MedXCell is a European cell therapy venture builder with a strong industrial mindset and a global perspective. Our focus is on technologies, techniques or novel applications in major diseases such as cancer, autoimmune, neurological and degenerative disorders. Established in 2018, we have offices in Switzerland, the EU (France) and the US (Cambridge, MA) and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development and funding capabilities. Biotechnology, Cell Therapy, Immunotherapy, NK Cells, Mesenchymal Stromal Cells, Immuno-oncology, and Osteoarthritis 425 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 8 |
 | Flindr Therapeutics Flindr develops first-in-class precision oncology therapies identified through the Immunogram Drug Discovery Engine Flindr Therapeutics, based in Oss in the Netherlands, is a private pre-clinical biotech company developing next-generation precision oncology treatments. The Company, previously called Immagene, was spun out of the Netherlands Cancer Institute (NKI) and Oncode Institute in 2020, by founders Prof Daniel Peeper, Prof Christian Blank and Dr Maarten Ligtenberg. Flindr is actively building a pipeline of highly promising, first-in-class precision oncology therapies identified through the ImmunoGram Drug Discovery Engine. It is backed by V-Bio Ventures, Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future … 27 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 16 |